GASTROSTRAT

Welcome to the Brand page for “GASTROSTRAT”, which is offered here for Pharmaceutical preparations for the treatment of irritable bowel syndrome, crohn's disease, and pharmaceutical substances, for the prediction of response to anti-tumor necrosis factor, also known as tnf, therapies and sanitary preparations for the prediction of response to anti-tumor necrosis factor therapies; diagnostic preparations and substances for medical use; diagnostic kits consisting primarily of multiplex polymerase chain reaction reagents and biochip array reagents; clinical diagnostic preparations for medical use; clinical diagnostic reagents for medical in vitro and/or vivo use; diagnostic scanning agents for in-vivo use used for the prediction of response to anti-tumor necrosis factor therapies; diagnostic testing materials, diagnostic preparations, reagents and contrast media for medical use; clinical medical reagents; reagents for use in diagnostic tests for medical purposes; reagents for use with analyzers for medical purposes; parts and fittings for all the aforesaid goods, multiplex polymerase chain reaction reagents and biochip array reagents; chemical reagents for medical purposes; enzymes for medical purposes;chemicals used in industry, science, photography, agriculture, horticulture and forestry; chemical reagents other than for medical purpose; enzymes for scientific and research purposes and proteins for industrial use; diagnostic preparations for scientific purposes; clinical diagnostic preparations or reagents other than for medical use; diagnostic preparations, diagnostic scanning agents; diagnostic testing materials, diagnostic preparations, reagents and contrast media other than for medical use; chemical reagents for use in diagnostic tests, other than for medical use; clinical diagnostic reagents for laboratory in vitro and/or vivo use;medical services; providing health advice and information services; medical care services; health clinic services; healthcare services, geriatric health care, physical therapy; medical health assessment services, providing prediction of response to anti-tumor necrosis factor therapies; diagnostic health screening services in the field of irritable bowel syndrome, crohn's disease; medical testing for prediction of response to therapy; medical diagnostic testing services; genetic testing for medical for medical purposes; medical clinics; advice, information and consultancy services for all of the aforesaid services;scientific and technological services, research and design in the field of irritable bowel syndrome, crohn's disease; medical research services; clinical research services, conducting clinical trials for others; biological research; conducting clinical trials for others, analysis, management and reporting of clinical data; consulting services in the field of quality assessment services for clinical laboratories; chemical research; chemical laboratory services; chemical analysis; scientific and medical laboratory services for analytical testing; medical laboratory services; biochemistry research and consultant advisory services; conducting clinical trials for others; providing computer aided diagnostic testing services for predicting response to anti-tumor necrosis factor therapies for others in the field of science and research related thereto; scientific and technological services, development of test equipment for medical apparatus for others; advice, information and consultancy services relating to all the aforesaid services;.

Its status is currently believed to be active. Its class is unavailable. “GASTROSTRAT” is believed to be currently owned by “Randox Laboratories Ltd”.